Microsoft word - 英文cv_薬・上村和秀2012-07-19.doc

Faculty of Pharmaceutical Sciences, University of Shizuoka 52-1 Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8526 B.A. in Pharmaceutical chemistry, Kyoto University 1993 M.Sc. in Pharmaceutical chemistry, Kyoto University 1995 Ph.D. in Pharmaceutical chemistry, Kyoto University 1998 CURRENT POSITION: Associate Professor of Pharmaceutical Sciences, Associate Professor of Pharmaceutical Sciences, Research Associate of Cell Biology, Albert Einstein College Instructor of Pharmaceutical Sciences, Kyoto University 1998-2002; Research Fellow of the Japan Society for the Promotion of Member of Pharmaceutical Society of Japan Member of Japanese Society of Carbohydrate Research PUBLICATIONS: “Sairei-to Ameliorates Rat Peritoneal Fibrosis Partly through Suppression of Oxidative Stress.” Kitamoto M, Kato K, Sugimoto A, Kitamura H, Uemura K, Takeda T, Wu C,
Nogaki F, Morimoto T, Ono T. Nephron Experimental Nephrology 117: e71-e81.
(2011)
“Lipopolysaccharide-triggered acute aggravation of mesangioproliferative glomerulonephritis through activation of coagulation in a high IgA strain of ddY mice.” Shimosawa M, Sakamoto K, Tomari Y, Kamikado K, Otsuka H, Liu N, Kitamura H,
Uemura K, Nogaki F, Mori N, Muso E, Yoshida H, Ono T.
Nephron Experimental Nephrology 112: e81-e91. (2009)
“Tissue factor and factor V involvement in rat peritoneal fibrosis.” Saito H, Kitamoto M, Kato K, Liu N, Kitamura H, Uemura K, Nogaki F, Takeda T, Mori N, Ono T. Peritoneal Dialysis International 29: 340-351. (2009)
“Serofendic acid protects from iodinated contrast medium and high glucose probably
against superoxide production in LLC-PK1 cells.” Kitamura O, Uemura K, Kitamura H,
Sugimoto H, Akaike A, Ono T. Clinical and Experimental Nephrology 13: 15-24.
(2009)

“Roles of Pofut1 and O-fucose in mammalian Notch signaling.” Uemura K, Stahl M,
Ge C, Shi S, Tashima Y, Stanley P. The Journal of Biological Chemistry 283:
13638-13651. (2008) “Soluble fibrin formation in the mesangial area of IgA nephropathy.” Liu N, Mori N, Iehara N, Uemura K, Fukastu A, Kita T, Matsuda M, Ono T.
Clinical and Experimental Nephrology 11, 71-76. (2007)
“The Na+-excreting efficacy of indapamide in combination with furosemide in massive
edema.” Tanaka M, Oida E, Nomura K, Nogaki F, Fukatsu A, Uemura K, Yashiro M,
Kimura T, Muso E, Ono T. Clinical and Experimental Nephrology 9, 122-126. (2005)
“Superoxide production from human polymorphonuclear leukocytes by human mannan-binding protein (MBP).” Uemura K, Yamamoto H, Nakagawa T, Nakamura K, Kawasaki N, Oka S, Ma BY, Kawasaki T. Glycoconjugate Journal 21, 79-84. (2004)
“Antitumor activity of mannan-binding protein.” Nakagawa T, Kawasaki N, Ma BY,
Uemura K, Kawasaki T. Methods in Enzymology 363, 26-33. (2003)
“Preparation of recombinant mannan-binding protein with a native oligomeric
structure.” Uemura K, Ma BY, Nakagawa T, Kawasaki N, Kawasaki T. Methods in Enzymology 363, 16-26. (2003)
“Role of mannan-binding protein, MBP, in innate immunity.” Nakagawa T, Ma BY,
Uemura K, Oka S, Kawasaki N, Kawasaki T. Anticancer Research 23, 4467-4471.
(2003)
“High mannose glycans and sialic acid on gp120 regulate binding of mannose-binding lectin (MBL) to HIV type 1.” Hart ML, Saifuddin M, Uemura K, Bremer EG, Hooker B, Kawasaki T, Spear GT. AIDS Research and Human Retroviruses 18, 1311-1317.
(2002)
“L-MBP is expressed in epithelial cells of mouse small intestine.” Uemura K, Saka M,
Nakagawa T, Kawasaki N, Thiel S, Jensenius JC, Kawasaki T.
The Journal of Immunology 169, 6945-6950. (2002)
“Tail-vein injection of mannan-binding lectin DNA leads to high expression levels of multimeric protein in liver.” Vorup-Jensen T, Jensen UB, Liu H, Kawasaki T, Uemura K, Thiel S, Dagnaes-Hansen F, Jensen TG. Molecular Therapy 3, 867-874. (2001)
“Recombinant expression of human mannan-binding lectin.” Vorup-Jensen T, Sorensen
ES, Jensen UB, Schwaeble W, Kawasaki T, Ma Y, Uemura K, Wakamiya N, Suzuki Y,
Jensen TG, Takahashi K, Ezekowitz RA, Thiel S, Jensenius JC.
International Immunopharmacology 1, 677-687. (2001)
“Antitumor activity of mannan-binding protein in vivo as revealed by a virus expression system: mannan-binding proteindependent cell-mediated cytotoxicity.” Ma Y, Uemura K, Oka S, Kozutsumi Y, Kawasaki N, Kawasaki T. Proceedings of the National
Academy of Sciences of the United States of America
96, 371-375. (1999)
“Characterization of human serum mannan-binding protein promoter.” Naito H, Ikeda
A, Hasegawa K, Oka S, Uemura K, Kawasaki N, Kawasaki T.
The Journal of Biochemistry 126, 1004-1012. (1999)
“Metabolic properties of normal and mutant mannan-binding proteins in mouse plasma.” Naito H, Ma Y, Uemura K, Arano Y, Kawasaki T. Biochemical and Biophysical Research Communications 256, 231-234. (1999)
“A unique CD45 glycoform recognized by the serum mannan-binding protein in
immature thymocytes.” Uemura K, Yokota Y, Kozutsumi Y, Kawasaki T.
The Journal of Biological Chemistry 271, 4581-4584. (1996)

Source: http://eng.u-shizuoka-ken.ac.jp/file/p_uemura_kazuhide.pdf

Microsoft word - 228.doc

Título: Um Estudo da Inserção dos Medicamentos Genéricos no Mercado Brasileiro. Autores: Fernando Nascimento Zatta (*) Hercules Vander de Lima Freire (**) Marcio Luiz de Castro (***) Moises Brasil Coser (****) Álvaro Ricardino (*****) País: Brasil FUCAPE – Fundação Instituto Capixaba de Pesquisas em Contabilidade, Economia e Finanças; (*) Mestrando da FUC

pb-begunje.si

NEVROLEPTI^NO ZDRAVLJENJE PRI OTROCIH Mojca Brecelj - Kobe IZVLE^EK V prispevku so poleg uvodnih razmi{ljanj o psihofarmakoterapijiotrok podane {e nekatere zna~ilnosti farmakodinamike in farmakokinetikepsihotropnih zdravil pri otrocih. Podane so tudi indikacije za zdravljenje znevroleptiki, po simptomih in nozolo{kih enotah. Navedena so posame-zna zdravila, njihovo predpisovanje i

Copyright © 2018 Predicting Disease Pdf